比较香港肝癌分期和巴塞罗那肝癌分期对TACE后生存的预测作用

发布时间：2018-04-25 12:35

本文选题：原发性肝癌 + 肝动脉化疗栓塞　；参考：《介入放射学杂志》2017年12期

【摘要】：目的比较香港肝癌分期(HKLC)和巴塞罗那肝癌(BCLC)分期对TACE治疗原发性肝癌预后判断能力的差别。方法回顾性分析2008年8月—2015年12月间182例初发的行TACE治疗的原发性肝癌患者,按两种分期方法完成分期评分,Kaplan-Meier分析计算两种分期方法各分期间的中位生存时间,并计算各分期系统似然比(LR)χ~2值、赤池信息量准则(AIC)和Harrell C值。结果两种分期方法各分期间的生存时间差异有统计学意义(P0.001)。HKLC分期系统的AIC、LRχ~2及Harrell C值分别是1 360、66.6、0.813,而BCLC的AIC、LRχ~2及Harrell C值分别为1365、61.8、0.772。结论相对于BCLC分期,HKLC分期更适合预测国内行TACE治疗的原发性肝癌患者的生存时间。
[Abstract]:Objective to compare the prognostic ability of TACE in the treatment of primary liver cancer (HCC) in Hong Kong (HK LC) and Barcelona hepatocarcinoma (FC C). Methods A total of 182 patients with primary liver cancer treated with TACE from August 2008 to December 2015 were retrospectively analyzed. Kaplan-Meier analysis and Kaplan-Meier analysis were performed to calculate the median survival time of the two staging methods. The values of 蠂 ~ 2, AIC-C and Harrell C were calculated. Results there were significant differences in survival time between the two staging methods (P 0.001. HKLC staging system). The values of AICLR 蠂 2 and Harrell C in the staging system were 1 360 / 66.6 / 0.813, respectively, while the BCLC's AICLR 蠂 2 and Harrell C values were 1 365 / 61.80.772, respectively. Conclusion compared with BCLC staging and HKLC staging, it is more suitable to predict the survival time of patients with primary liver cancer treated with TACE in China.
【作者单位】：东南大学附属中大医院介入与血管外科;
【分类号】：R735.7

【相似文献】